Community-acquired pneumonia
Conditions
Interventions
None listed
Sponsors
Matsuki Taizo
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults aged >=18 years. 2. Clinical signs and/or symptoms of an acute respiratory illness, as defined by >=1 of the following: - New or worsening shortness of breath in the past 7 days - New or worsening cough in the past 7 days - New or worsening sputum production in the past 7 days - New or worsening chest pain in the past 7 days - Tachypnea to respiratory rate >=22 breaths/min not known to be chronic - Hypoxia to SpO2 =1 of the following: - Sublingual body temperature >=37.5 C (99.5 F) or 10.7 or 10 mg/L - Altered mental status 4. Radiologic evidence of pneumonia interpreted by a radiologist, defined as >=l of the following findings on chest x-ray (CXR) or computed tomography (CT) completed in the outpatient setting or within 72 hours before or after hospital admission: - Pulmonary infiltrate not known to be chronic - Pulmonary opacity not known to be chronic (including ground glass opacities on CT) - Pulmonary consolidation not known to be chronic 5. Patients willing and able to give informed consent written in Japanese for participation in the study.
Exclusion criteria
Exclusion criteria: - Enrollment in this study within the past 30 days. - Development of pneumonia (as defined in the inclusion criteria) more than 48 hours after hospital admission (pneumonia developed 48 hours after admission will be considered HAP). - Inability to obtain consent from patient or surrogate for this study within 72 hours of hospital admission (including time at a transferring hospital prior to admission at a study hospital). - Inability or unwillingness of the patient to provide a urine sample within 72 hours of hospital admission (including time at a transferring hospital prior to admission at a study hospital) or the patient is not able or unwilling to provide a urine sample at the day when patient is diagnosed with PP in outpatient clinic. - Non-pneumonia illness completely explains the acute symptoms. Alternative non-pneumonia illnesses could include: pulmonary embolism, acute heart failure, lung cancer, and pulmonary hemorrhage.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To describe the demographic and clinical characteristics of adults >=18 years old hospitalized with either non-pneumococcal or pneumococcal community-acquired pneumonia (CAP), including both bacteremic and non-bacteremic pneumococcal CAP. - To determine the prevalence of pneumococcal serotypes included in the pneumococcal conjugated vaccines in adults >=18 years old hospitalized with pneumococcal CAP. - To assess in-hospital clinical outcome including in-hospital mortality, ICU admission, and length of hospitalization in adults >=18 years old hospitalized with pneumococcal CAP, including both bacteremic and non-bacteremic pneumococcal CAP. | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the hospital specific incidence of bacteremic and non-bacteremic pneumococcal CAP. | — |
Contacts
Public ContactMasahiro Sakano
CMIC Co., Ltd.
Outcome results
None listed